Latest BIOGEN Científica News & Updates

See the latest news and media coverage for BIOGEN. We track all announcements, press releases, and industry mentions in real time, all in one place.

BIOGEN Científica (BIOGEN)

Laboratory reagent, equipment, and consumables supplier

biogen.es

Headquarters: Madrid, Spain
Founded year: 1989
Company type: Private company
Number of employees: 14–50
Industry: Medical Equipment, Supplies & Distribution

Last updated October 28

Latest news about BIOGEN Científica (BIOGEN)

In short: Biogen advanced lupus, Alzheimer's and SMA pipeline while sealing Alteogen deal

Company announcements

October 28 BIOGEN

Biogen presents solutions at the IUMS Congress 2026

The team will showcase VANTAstar and ACU in Lisbon from November 4 to 6 alongside BMG LABTECH.

October 26 BIOGEN

Biogen presents technology at the GEIVEX symposium

BIOGEN Scientific accompanied EXODUS BIO at the 8th GEIVEX Symposium to showcase automated exosome isolation solutions that simplify research.

September 14 BIOGEN

BIOGEN Científica participates in the SEBBM congress

Share biomedical innovation and connect with sector professionals alongside BLT Imaging partners in Tarragona.

September 1 BIOGEN

BIOGEN Scientific Commercializes the Minitron SE Incubator

The limited version features a fixed configuration optimized for simple processes and will be available until December 18, 2026.

Media coverage

March 30 FierceBiotech

Biogen's litifilimab sparkles in midphase lupus trial, raising hopes for pivotal readout

Biogen's lupus drug candidate litifilimab has improved outcomes in another phase 2 trial, adding to the momentum behind a program barreling toward pivotal data in...

March 26 Chosunbiz

Alteogen seals Biogen deal to develop SC biologics, eyes up to 820b KRW

Alteogen said on the 25th that it signed an exclusive license agreement with Biogen, a U.S. pharmaceutical company, to develop and commercialize subcutaneous injection (SC...

March 19 Yahoo Finance

Biogen Conference: Tau ASO CELIA Updates, Pre-Symptomatic Leqembi, SMA Phase 3 Plans

BIIB080 / CELIA: Biogen's tau ASO BIIB080 (CELIA) is an 18-month proof-of-concept test of intracellular tau lowering — phase 1b showed ~60% CSF tau knockdown...

March 16 Yahoo Finance

Biogen (BIIB) Valuation Check As New SMA Data And Phase 3 Plans Draw Fresh Growth Focus

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Biogen (BIIB) has put fresh attention on its...

Never miss news about BIOGEN

Track BIOGEN and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

BIOGEN competitors & trending companies

Browse news for competitors to BIOGEN and other trending companies.